According to IMS, for the 12 months ending August 2015, the US market for Chlorothiazide approximated $29m.
As with all products in Sagent’s portfolio, Chlorothiazide features Sagent’s PreventIV MeasuresSM Packaging and Labeling, designed to help reduce the risk of medication errors.
About Chlorothiazide Sodium for Injection, USP
Chlorothiazide Sodium for Injection, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.
Chlorothiazide Sodium for Injection, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.